SCHEMBL19355131

SCHEMBL19355131

CNC(=O)c1c(F)cnc2c(C(C)CCNc3cc(-c4ccc(OC)c(OC)n4)ncn3)cccc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.33
RPS6KB1 P23443 3/20 0.32
FAAH O00519 2/20 0.32
PRKDC P78527 2/20 0.32
ROCK2 O75116 1/20 0.32
ROCK1 Q13464 1/20 0.32
MAP2K7 O14733 2/20 0.32
CDK9 P50750 1/20 0.32
AURKA O14965 2/20 0.31
AURKB Q96GD4 2/20 0.31
ALK Q9UM73 1/20 0.31
GRM7 Q14831 1/20 0.31
RIPK1 Q13546 1/20 0.31
ABL1 P00519 1/20 0.31
BCR P11274 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17634710 0.93 PRKDC (0.38) HPGDSRPS6KB1FAAHPRKDCCDK9
SCHEMBL19905144 0.86 CYP1A2 (0.36) HPGDSMAP2K7CDK9CYP1A2CYP3A4
SCHEMBL19355580 0.86 GRM5 (0.34) HPGDSPRKDCROCK2ROCK1ABL1
SCHEMBL19355142 0.85 RIPK1 (0.37) RPS6KB1PRKDCRIPK1ABL1BCR
SCHEMBL19355582 0.83 PRKDC (0.39) PRKDCROCK2ROCK1
SCHEMBL19355624 0.83 GCK (0.39) FAAHPRKDCABL1BCR
SCHEMBL17634849 0.82 PRKDC (0.44) FAAHPRKDCCDK9GRM7CYP1A2
SCHEMBL19355149 0.82 PRKDC (0.39) FAAHPRKDCABL1BCRCYP1A2
SCHEMBL19905204 0.81 PRKDC (0.37) FAAHPRKDCABL1BCRCYP1A2
SCHEMBL19355648 0.80 PRKDC (0.38) FAAHPRKDCABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170258789-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258789-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK HPGDS 918/4885RPS6KB1 828/4885FAAH 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.